ArticleCellular & molecular biology letters2025
The novel circular RNA circG6pc attenuates oxidative stress and mitochondrial damage through miR-7018-5p/Aldh6a1 axis in kidney fibrosis.
Article in Cellular & molecular biology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Renal gluconeogenesis: a key metabolic hub in health and kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- The Mechanism and Application of Traditional Chinese Medicine Nano-Formulations in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) is characterized by progressive renal fibrosis, which contributes to disease progression and ultimately leads to kidney failure. Circular RNAs (circRNAs) are key regulators in various fibrotic diseases, showing different expression patterns in different organs. However, the exact role and mechanisms of circRNAs in renal fibrosis are still not fully understood.
methodsWe analyzed circRNA expression in kidney tissues from unilateral ureteral obstruction (UUO) mice using RNA sequencing (RNA-seq). Bioinformatics analysis identified a significant downregulation of circG6pc in fibrotic kidneys. The role and mechanisms by which circG6pc inhibits renal fibrosis were explored both in vivo and in vitro. To further validate our findings, we employed gene overexpression and knockdown, along with immunohistochemistry, dual-luciferase reporter assays, RNA antisense purification (RAP) assays, RNA immunoprecipitation (RIP) assays, western blotting, and RT-qPCR.
resultsCircG6pc is significantly downregulated in fibrotic kidneys, and overexpression of circG6pc can notably improve renal fibrosis, mitochondrial dysfunction, and oxidative stress damage. Mechanistically, circG6pc acts as a sponge, directly binding to miR-7018-5p, thereby relieving its inhibitory effect on Aldh6a1 expression. The upregulation of Aldh6a1 promotes mitochondrial biogenesis, corrects mitochondrial dynamics imbalance, alleviates oxidative stress induced by mitochondrial dysfunction, and ultimately suppresses the progression of renal fibrosis.
conclusionsThese findings reveal the molecular mechanism by which circG6pc alleviates mitochondrial dysfunction and oxidative stress through the miR-7018-5p/Aldh6a1 axis, thereby inhibiting renal fibrosis. This provides a potential new strategy for the treatment of progressive CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.